These results suggested that IL-35 restrains RA angiogenesis and inflammation by downregulating basal and VEGF-induced Ang2 secretion as well as disrupting Ang2/Tie2 signal transduction. Our findings extend current understanding of mechanisms regulating RA angiogenesis and may support development of novel angiogenesis-targeting therapeutics for RA treatment.
No takes yet. Share an insight, caveat, or question.
Jiang et al. (2016) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: